Medications for Acromegaly

10 results

  • Bromocriptine mesylate (bromocriptine mesylate)

    (Bromocriptine mesylate)
    Zydus Pharmaceuticals USA Inc.
    Usage: Bromocriptine mesylate capsules are indicated for treating hyperprolactinemia-related disorders (e.g., amenorrhea, infertility, hypogonadism), acromegaly, and symptoms of Parkinson's disease. It may be used with levodopa to enhance efficacy and reduce side effects, especially in patients experiencing tolerance or "end of dose failure."

  • Bromocriptine mesylate (bromocriptine mesylate)

    (Bromocriptine mesylate)
    Sandoz Inc
    Usage: Bromocriptine mesylate tablets are indicated for treating hyperprolactinemia-related dysfunctions (e.g., amenorrhea, infertility), acromegaly, and symptoms of Parkinson's disease. They help reduce tumor size in prolactin-secreting adenomas and enhance effects of levodopa in Parkinson's, while potentially reducing levodopa dosage and adverse reactions.

  • Lanreotide acetate (lanreotide acetate)

    (LANREOTIDE ACETATE)
    Cipla USA Inc.
    Usage: Lanreotide Injection is indicated for the long-term treatment of acromegaly in patients not responding to surgery/radiotherapy, and for unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. It also treats adults with carcinoid syndrome, reducing the need for short-acting somatostatin analogs.

  • Octreotide acetate (octreotide acetate)

    (Octreotide acetate)
    Wockhardt Limited
    Usage: Octreotide acetate is indicated for treating acromegaly in patients who have not responded adequately to surgery or other treatments, as well as for managing severe diarrhea and flushing in metastatic carcinoid tumors and profuse watery diarrhea in VIP-secreting tumors. It does not affect tumor size or growth.

  • Octreotide acetate (octreotide acetate)

    (octreotide acetate)
    Hainan Shuangcheng Pharmaceuticals Co., Ltd.
    Usage: Octreotide acetate injection is indicated for reducing growth hormone and IGF-1 levels in acromegaly patients not responsive to other treatments, and for managing severe diarrhea and flushing in metastatic carcinoid tumors and watery diarrhea in VIPoma-associated tumors. Limitations exist regarding tumor size reduction and clinical improvement.

  • Octreotide acetate (octreotide acetate)

    (octreotide acetate)
    Mylan Institutional LLC
    Usage: Octreotide acetate injection is used to reduce growth hormone and IGF-1 levels in acromegaly patients who have not responded to other treatments. It also treats severe diarrhea and flushing from metastatic carcinoid tumors and profuse watery diarrhea from vasoactive intestinal peptide tumors (VIPomas).

  • Octreotide acetate (octreotide acetate)

    (Octreotide Acetate)
    Meitheal Pharmaceuticals, Inc.
    Usage: Octreotide Acetate Injection is indicated for managing acromegaly in patients unresponsive to other treatments, treating severe diarrhea and flushing from metastatic carcinoid tumors, and addressing profuse watery diarrhea from vasoactive intestinal peptide tumors (VIPomas). Clinical trials did not confirm its impact on tumor size or growth rate.

  • R-gene (arginine hydrochloride)

    (Arginine Hydrochloride)
    Pharmacia & Upjohn Company LLC
    Usage: R-Gene® 10 is indicated as an intravenous stimulant for the release of human growth hormone (HGH) to diagnose pituitary function in conditions like panhypopituitarism, dwarfism, and acromegaly. It aids in confirming HGH reserve deficiencies when previous tests indicate potential issues. Follow-up testing may be required.

  • Somatuline depot

    (lanreotide acetate)
    Ipsen Biopharmaceuticals, Inc.
    Usage: SOMATULINE DEPOT is indicated for long-term treatment of acromegaly, unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome in adults. It aims to normalize growth hormone levels, improve progression-free survival in GEP-NETs, and reduce the need for short-acting somatostatin analog rescue therapy in carcinoid syndrome.

  • Somavert

    (pegvisomant)
    Pharmacia & Upjohn Company LLC
    Usage: SOMAVERT is indicated for treating acromegaly in patients unresponsive to surgery or radiation, or when these options are unsuitable. The treatment aims to normalize serum insulin-like growth factor-1 (IGF-1) levels.